Emergent BioSolutions Inc. (NYSE:EBS) Shares Acquired by State of Michigan Retirement System

State of Michigan Retirement System lifted its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 2.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,800 shares of the biopharmaceutical company’s stock after buying an additional 400 shares during the quarter. State of Michigan Retirement System’s holdings in Emergent BioSolutions were worth $1,561,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Virginia Retirement Systems ET AL grew its position in shares of Emergent BioSolutions by 19.8% during the first quarter. Virginia Retirement Systems ET AL now owns 21,200 shares of the biopharmaceutical company’s stock worth $1,970,000 after buying an additional 3,500 shares in the last quarter. Oakworth Capital Inc. acquired a new position in shares of Emergent BioSolutions during the first quarter worth about $41,000. Centaurus Financial Inc. acquired a new position in Emergent BioSolutions in the first quarter valued at approximately $871,000. Chatham Capital Group Inc. boosted its holdings in Emergent BioSolutions by 4.7% in the first quarter. Chatham Capital Group Inc. now owns 27,260 shares of the biopharmaceutical company’s stock valued at $2,533,000 after purchasing an additional 1,225 shares in the last quarter. Finally, Meeder Asset Management Inc. boosted its holdings in Emergent BioSolutions by 3,013.7% in the first quarter. Meeder Asset Management Inc. now owns 3,176 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 3,074 shares in the last quarter. 80.23% of the stock is owned by institutional investors and hedge funds.

In other news, Director Sue Bailey sold 8,168 shares of the company’s stock in a transaction that occurred on Thursday, March 4th. The stock was sold at an average price of $92.37, for a total transaction of $754,478.16. Following the completion of the sale, the director now owns 24,427 shares in the company, valued at $2,256,321.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 14.10% of the stock is owned by corporate insiders.

EBS stock opened at $62.00 on Monday. The company has a market capitalization of $3.32 billion, a P/E ratio of 19.94 and a beta of 1.26. Emergent BioSolutions Inc. has a twelve month low of $55.07 and a twelve month high of $137.61. The business has a 50 day simple moving average of $72.01 and a 200-day simple moving average of $90.24. The company has a current ratio of 3.20, a quick ratio of 2.30 and a debt-to-equity ratio of 0.68.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Wednesday, April 28th. The biopharmaceutical company reported $1.53 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.56. Emergent BioSolutions had a return on equity of 26.68% and a net margin of 12.50%. The business had revenue of $343.00 million during the quarter, compared to analysts’ expectations of $368.62 million. Research analysts predict that Emergent BioSolutions Inc. will post 6.94 EPS for the current fiscal year.

EBS has been the subject of a number of research analyst reports. Benchmark lowered their price target on Emergent BioSolutions from $150.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 30th. Chardan Capital lowered their price target on Emergent BioSolutions from $112.00 to $92.00 and set a “buy” rating for the company in a report on Thursday, May 6th. Wells Fargo & Company lowered their price target on Emergent BioSolutions from $70.00 to $64.00 in a report on Wednesday, May 5th. Guggenheim lowered their price target on Emergent BioSolutions from $130.00 to $110.00 and set a “buy” rating for the company in a report on Wednesday, April 14th. Finally, Argus reissued a “hold” rating on shares of Emergent BioSolutions in a report on Tuesday, May 11th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $98.00.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Featured Article: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent BioSolutions Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.